Nabil Zeineh, MD
Cardiovascular Disease · Robbinsdale, MNNPI 1679769418
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,822 of the $3,863 with a category attached, or 73.0%. 4 manufacturers reported payments, led by Boston Scientific at 49.1% of the total.
Across 32 payments — averaging $120.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Atricure, Inc.$97
- Abbott$44
Across 56 payments — averaging $4259.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$239K
What the payments were for
- Travel & lodging$2,82273%
- Food & beverage$1,04127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $1,899 |
| Medtronic | 13 | $1,824 |
| Atricure, Inc. | 1 | $97 |
| Abbott | 3 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM$1,572
- EVERA MRI XT DR SURESCAN$1,263
- AURORA EV-ICD MRI SURESCAN$222
- TYRX$111
How this compares
$3,863 in reported general payments places this provider in the 65th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $255,139 |
| XareltoRivaroxaban | 81 | $100,329 |
| JardianceEmpagliflozin | 17 | $24,895 |
| Metoprolol Succinate | 331 | $7,750 |
| Flecainide Acetate | 59 | $2,605 |
| SotalolSotalol Hcl | 66 | $1,484 |
| Atorvastatin Calcium | 63 | $1,185 |
| Bumetanide | 31 | $976 |
| Losartan Potassium | 47 | $729 |
| Lisinopril | 62 | $666 |
| Rosuvastatin Calcium | 50 | $619 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $569 |
| Warfarin Sodium | 36 | $495 |
| Amlodipine Besylate | 57 | $484 |
| Torsemide | 19 | $471 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Robbinsdale
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.